Novel dual-hormone insulin therapy offers hope for better management of type 1 diabetes

Drs. Ahmad Haidar, Laurent Legault, Michael Tsoukas and Jean-Franҫois Yale are a team of JDRF-funded researchers at McGill University (Montreal) who are the first to test the addition of pramlintide (a synthetic form of amylin, which is a hormone co-secreted with insulin by the healthy pancreas) to ...

A letter to the T1D community from JDRF President and CEO Dave Prowten

I have been blown away by the strength, resilience and generosity demonstrated by you, our JDRF family. I am reminded of how privileged we are to have your continued support. 

Severe lows? Spray it in the nose! New Nasal Glucagon for severe hypoglycemia available in Canada!

A Look into the 2020 Pre-Budget Consultations

JDRF President and CEO Dave Prowten testified recently in front of the Standing Committee on Finance as part of their 2020 Pre-Budget Consultations. Also appearing on JDRF’s behalf was Angie Sullivan, parent of a child with type 1 diabetes (T1D).

Meet the 2020 Manitoba Lobby Day Delegates!

We’re so happy to share our 8 finalists with you – meet our 2020 Manitoba Lobby Day Delegates!

#AccessforAll recommendation presented to Ontario's Minister of Finance

She was the youngest person in the room, and her presentation was met with resounding applause from the entire audience. Fourteen-year old Anne Pettigrew made an impressive and compelling presentation at last month’s Ontario pre-budget consultations in Scarborough.

Finding strength in adversity: Newly diagnosed teen competes in 2020 Youth Olympics

Fifteen-year-old Kamilla Kozuback recalls fighting back tears as she successfully landed her final jump at the 2020 Youth Olympic Games this past January, placing eighth as one of the youngest snowboarders in the competition to ever represent Canada.

JDRF celebrates top 10 advances in research

Now that 2019 has drawn to a close, we want to take a moment and extend our sincere thanks and appreciation for your support of our efforts in finding cures for type 1 diabetes (T1D) and improving the lives of the more than 300,000 Canadians and their families touched by this disease.